Deals In Depth: February 2014
Actavis significantly improved its US presence though its $24 billion purchase of Forest Labs, while Myriad exercised its option to buy fellow molecular diagnostics company Crescendo. Public offerings – IPOs and follow-ons – dominated both biopharma and device financing.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.